Theriva Biologics Stock Today
TOVX Stock | USD 1.28 0.02 1.59% |
Performance0 of 100
| Odds Of DistressOver 81
|
Theriva Biologics is trading at 1.28 as of the 24th of November 2024; that is 1.59% up since the beginning of the trading day. The stock's open price was 1.26. Theriva Biologics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. Equity ratings for Theriva Biologics are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 5th of December 2022 and ending today, the 24th of November 2024. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 18th of December 2006 | Category Healthcare | Classification Health Care |
Theriva Biologics Inc., a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. Theriva Biologics Inc. is headquartered in Rockville, Maryland. Theriva Biologics operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 2.78 M outstanding shares of which 90.95 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover. More on Theriva Biologics
Moving together with Theriva Stock
Moving against Theriva Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Theriva Stock Highlights
Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Management, Biotech, Computers, Health Care, Biotechnology, Biotechnology, Healthcare, Computing (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Theriva Biologics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Theriva Biologics' financial leverage. It provides some insight into what part of Theriva Biologics' total assets is financed by creditors.
|
Theriva Biologics (TOVX) is traded on NYSE MKT Exchange in USA. It is located in 9605 Medical Center Drive, Rockville, MD, United States, 20850 and employs 22 people. Theriva Biologics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 3.56 M. Theriva Biologics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 2.78 M outstanding shares of which 90.95 K shares are at this time shorted by private and institutional investors with about 0.03 trading days to cover.
Theriva Biologics currently holds about 52.27 M in cash with (19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.3, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Theriva Biologics Probability Of Bankruptcy
Ownership AllocationTheriva Biologics has 10.48 % of its outstanding shares held by insiders and 21.2 % owned by institutional holders.
Check Theriva Ownership Details
Theriva Biologics Historical Income Statement
Theriva Stock Against Markets
Theriva Biologics Corporate Management
Steven CPA | CFO, CEO | Profile | |
Vincent Perrone | Director Communication | Profile | |
Frank Tufaro | Chief Officer | Profile | |
Vince Wacher | Head Development | Profile | |
Lara Guzman | Director Operations | Profile | |
Ramon Alemany | Senior Board | Profile | |
Michael MD | Senior Development | Profile |
Additional Tools for Theriva Stock Analysis
When running Theriva Biologics' price analysis, check to measure Theriva Biologics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Theriva Biologics is operating at the current time. Most of Theriva Biologics' value examination focuses on studying past and present price action to predict the probability of Theriva Biologics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Theriva Biologics' price. Additionally, you may evaluate how the addition of Theriva Biologics to your portfolios can decrease your overall portfolio volatility.